Regeneron Other Stockholder Equity from 2010 to 2024
| REGN Stock | USD 1,003 2.16 0.22% |
Other Stockholder Equity | First Reported 1990-12-31 | Previous Quarter -1.2 B | Current Value -914.1 M | Quarterly Volatility 1.2 B |
Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 442.1 M, Interest Expense of 76.7 M or Total Revenue of 13.8 B, as well as many indicators such as Price To Sales Ratio of 6.79, Dividend Yield of 0.0 or PTB Ratio of 5.22. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
Regeneron | Other Stockholder Equity |
Latest Regeneron Pharmaceuticals' Other Stockholder Equity Growth Pattern
Below is the plot of the Other Stockholder Equity of Regeneron Pharmaceuticals over the last few years. It is Regeneron Pharmaceuticals' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regeneron Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Other Stockholder Equity | 10 Years Trend |
|
Other Stockholder Equity |
| Timeline |
Regeneron Other Stockholder Equity Regression Statistics
| Arithmetic Mean | 1,393,246,667 | |
| Geometric Mean | 989,275,695 | |
| Coefficient Of Variation | 122.19 | |
| Mean Deviation | 1,488,968,000 | |
| Median | 1,763,508,000 | |
| Standard Deviation | 1,702,384,501 | |
| Sample Variance | 2898113T | |
| Range | 4.9B | |
| R-Value | (0.46) | |
| Mean Square Error | 2449475.6T | |
| R-Squared | 0.22 | |
| Significance | 0.08 | |
| Slope | (176,578,582) | |
| Total Sum of Squares | 40573581.8T |
Regeneron Other Stockholder Equity History
About Regeneron Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Regeneron Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Regeneron Pharmaceuticals investors use historical funamental indicators, such as Regeneron Pharmaceuticals's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Regeneron Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regeneron Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regeneron Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Stockholder Equity | -1.2 B | -1.1 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Regeneron Stock
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share 33.9 | Revenue Per Share 122.574 | Quarterly Revenue Growth (0.01) | Return On Assets 0.0774 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.